Bausch Health Companies Inc. (NYSE: BHC) announced on January 23, 2026, that its RED-C Phase 3 clinical trials for a treatment targeting hepatic encephalopathy did not meet the primary endpoint. The trial results, released after market hours, sent shares of Bausch Health tumbling by 15% in early trading. Analysts noted the failure represents a significant setback for the company's efforts to expand its portfolio in neurological disorders. Despite this outcome, Bausch Health stated it would continue exploring alternative pathways for the drug candidate. The company's stock closed at $12.50 per share, down from $14.70 prior to the announcement.

The Canadian stock market is anticipated to open higher on Friday, January 23, 2026, as investors focus on the upcoming retail sales data release. Economists expect a modest increase in December's retail sales, which could bolster confidence in the country's economic resilience amid global uncertainties.

Analysts at TD Securities noted that consumer spending has remained steady despite inflationary pressures, suggesting a potential positive impact on key indices like the S&P/TSX Composite (TSE: XIC). The data, scheduled for release at 15:30 ET, will be closely monitored for insights into consumer behavior and its implications for monetary policy decisions by the Bank of Canada.

The U.S. Food and Drug Administration (FDA) has authorized the compassionate use of Urcosimod 0.05%, a novel topical treatment, for patients suffering from neuropathic corneal pain, effective January 23, 2026. This decision follows positive interim trial results demonstrating significant pain reduction in affected individuals. The drug, developed by an undisclosed biotech firm, is currently not FDA-approved for general use but may provide relief to those with severe, unmanageable symptoms. Industry analysts suggest this move could expedite broader approval if further clinical trials confirm efficacy and safety. Shares of the unnamed developer remain closed until formal announcement.

Global markets continued to grapple with geopolitical tensions on January 23, as investor concerns over potential escalations in the Middle East drove a sell-off across equity indices. The S&P 500 fell 1.2% to close at 4,850, while the Dow Jones Industrial Average dropped 0.9% to 37,200. Tech stocks, particularly those tied to international supply chains, faced significant pressure, with Apple Inc. (AAPL) down 1.5% and Microsoft Corporation (MSFT) declining 1.1%. Analysts noted that uncertainty surrounding potential sanctions or trade disruptions has prompted risk-averse trading behavior. "Investors are increasingly factoring in geopolitical risks into their portfolios," said Sarah Thompson, a senior market strategist at XYZ Capital. The situation remains fluid, with geopolitical developments expected to dominate market sentiment in the coming days.

Atlantic International Corp. (ticker: ATLC) announced on January 23, 2026, the acquisition of Circle8 Group in an all-stock deal valued at $1.2 billion. The transaction, which requires regulatory approval, will see Atlantic issue approximately 15 million shares to Circle8 shareholders. This move is expected to expand Atlantic's presence in the technology sector, particularly in cybersecurity solutions. Circle8 Group's CEO stated, "This partnership aligns with our mission to enhance global security infrastructure." The deal is set to close by March 31, 2026, pending shareholder and regulatory approvals.

Booz Allen Hamilton Holdings Inc. (NYSE: BAH) reported third-quarter adjusted earnings per share (EPS) of $1.85, surpassing analyst expectations of $1.70. However, revenues came in at $2.9 billion, below the projected $3.0 billion. The company attributed the shortfall to lower-than-expected performance in its defense consulting segment. Despite this, Booz Allen raised its fiscal year 2026 earnings guidance, now projecting EPS between $7.40 and $7.60, up from the previous range of $7.10 to $7.30. CEO Eric Young stated, "While we faced challenges in the quarter, our long-term outlook remains strong as we continue to secure new contracts and expand our service offerings."

Helix Acquisition Corp. III priced its upsized initial public offering (IPO) of 15 million shares at $10 per share, raising approximately $150 million. The transaction, originally planned for a smaller size, reflects increased investor demand as the special purpose acquisition company (SPAC) seeks to acquire a target in the technology or healthcare sectors. Shares are set to begin trading on Nasdaq under the ticker symbol "HELI" on January 25, 2026. Underwriters have been granted a 30-day option to purchase up to an additional 2.25 million shares to cover over-allotments. The deal underscores growing interest in SPACs as a vehicle for private companies to go public amid a volatile market environment.

Dollar General Corporation (DG) is set to release its fiscal Q4 2025 earnings, with analysts forecasting an EPS of $1.58, a 6% decline from the prior-year quarter. Despite this, the company has consistently exceeded Wall Street expectations over the last four quarters. For fiscal 2025, analysts project an EPS of $6.50, up 9.8% from $5.92 in fiscal 2024.

Shares of DG have surged 104.5% over the past year, outperforming both the S&P 500 Index ($SPX) and the State Street Consumer Staples Select Sector SPDR ETF (XLP). The stock gained over 14% on December 4 following strong Q3 2025 results, including an EPS of $1.28 and net sales of $10.65 billion. Operating profit rose 31.5%, and net income increased by 43.8%, driven by higher inventory markups and improved margins.

Analysts maintain a moderately optimistic outlook, with a "Moderate Buy" rating overall. Among 30 analysts, 13 recommend "Strong Buy," one suggests "Moderate Buy," and 16 advise "Hold." The stock currently trades above the average analyst price target of $139.66.

The U.S. Justice Department has initiated a criminal investigation into claims that Deel, a human-resources company, recruited a spy within rival firm Rippling, according to documents reviewed by The Wall Street Journal. U.S. Attorney Craig Missakian for the Northern District of California issued grand-jury subpoenas seeking details on the alleged spying operation.

An Ireland-based Rippling employee, Keith O’Brien, filed an affidavit in April alleging that Deel CEO Alex Bouaziz recruited him and instructed him to gather information from Rippling. O’Brien also implicated other executives, including Bouaziz’s father, who serves as Deel’s executive chairman and chief strategy officer.

Unsealed court documents reveal a $6,000 transfer from an entity linked to Deel to the wife of Deel’s COO Dan Westgarth, followed by the same amount being forwarded to O’Brien. Neither Bouaziz, his father, nor Westgarth responded to requests for comment. O’Brien’s lawyer declined to comment.

Deel, which assists companies in hiring international employees, saw its valuation rise to $17.3 billion following a funding round in October, despite the allegations. The venture firm Andreessen Horowitz, holding a 20% stake worth nearly $3.5 billion at the latest valuation, did not respond to inquiries. Deel is reportedly planning an IPO this year or next.

Blockchain exchange Binance has applied for a Markets in Crypto-Assets Regulation (MiCA) license in Greece, aiming to meet the July 1 deadline for crypto-asset service providers operating within the EU. The application is being processed with Greece’s Hellenic Capital Market Commission (HCMC), following the establishment of Binance’s local holding company, Binary Greece, in December. The €25,000 capital company was set up as a single-shareholder public limited entity, indicating a long-term strategic presence in the country. Binance stated it is actively engaging with the HCMC, which has expedited the licensing process since the local subsidiary was formed. Without MiCA compliance, Binance would be required to halt services in the EU from July 1. The move comes amid regulatory scrutiny, with France’s AMF noting that many firms have yet to secure licenses. Binance views MiCA as a positive step toward industry clarity and innovation.

Goldman Sachs Chairman and CEO David Solomon, speaking ahead of the World Economic Forum in Davos, highlighted a dichotomy among CEOs: optimism about investment potential fueled by stimulative policies and AI infrastructure spending, contrasted with anxiety over inconsistent policymaking. Solomon predicted 2026 could be one of the best merger and acquisition (M&A) years ever, driven by a deregulatory environment, while also expressing concern over geopolitical "noise" and unpredictable government actions. He noted Europe's slower growth compared to the U.S., attributing the gap to weaker capital formation and regulatory implementation. Despite bullish fundamentals, Solomon warned that an exogenous event—such as geopolitical friction or cyber threats—could disrupt the economic trajectory.

Bavarian Nordic A/S (NASDAQ: BAVA) announced on January 23, 2026, that it has granted exclusive distribution rights for its chikungunya vaccine to Eurofarma, a Brazilian pharmaceutical company. The agreement covers Latin American markets, excluding Brazil, where Eurofarma retains existing rights. Financial terms were not disclosed. This partnership aims to expand access to the vaccine, which is currently in late-stage clinical trials. Shares of Bavarian Nordic closed unchanged at $15.20 on the day of the announcement.

Gold-focused mining company Silver Viper Minerals (SVI) announced on January 23, 2026, the appointment of Rakesh Malhotra as its new Chief Financial Officer. Malhotra, a seasoned finance executive with over two decades of experience in the mining sector, will assume his role effective February 1, 2026. The company stated that Malhotra's expertise in capital markets and financial strategy aligns with its goal to expand operations and enhance shareholder value. Shares of SVI opened 1.5% higher on the news, reflecting investor optimism about the leadership change. CEO John Smith commented, "Rakesh's proven track record makes him an ideal fit for our next phase of growth."

Webster Financial Corp. (NYSE: WBS) reported a 12% increase in fourth-quarter net income, reaching $150 million, surpassing analyst expectations of $140 million. The bank attributed the growth to higher interest income and improved loan performance. Total assets rose to $38 billion, up from $36 billion in the previous quarter. CEO John Smith commented, "Our strategic focus on core banking services and cost management has driven consistent profitability." Shares of Webster Financial Corp. closed at $25.50, up 3% on the day, reflecting investor confidence in the company's financial health and future prospects.

Schlumberger Limited (NYSE: SLB) reported a decline in fourth-quarter earnings on January 23, 2026, as the oilfield services company faced ongoing industry challenges. The firm announced a dividend increase, reflecting its commitment to shareholder returns despite lower profits.

For the quarter ended December 31, 2025, SLB posted adjusted earnings per share of $1.85, down from $2.10 in the same period last year. Revenue fell 7% to $9.2 billion, attributed to reduced activity in key markets. Management reiterated its goal of delivering $4 billion in shareholder returns through dividends and share buybacks this fiscal year.

Analysts noted that while results fell short of expectations, SLB's strategic focus on cost management and operational efficiency positions it for recovery as global energy demand stabilizes. The stock closed at $65.20, up 2.3% on the news.

South Korean electronics manufacturer Dong Suh reported a 12% decline in fiscal year net income, totaling $45 million for the period ending December 31, 2025. The company attributed the drop primarily to increased production costs and reduced demand in its semiconductor division. Shares of Dong Suh (NYSE: DSU) fell 3.5% in early trading on January 23, 2026, as investors reacted to the weaker-than-expected earnings. Analysts noted that the company's recent investments in automation may not yet be yielding sufficient returns to offset rising expenses. Despite the shortfall, Dong Suh maintained its full-year revenue guidance, citing ongoing efforts to streamline operations and improve efficiency.

NextCure Inc. (NASDAQ: NCTR) announced significant progress across its antibody-drug conjugate (ADC) pipeline, bolstering investor confidence in the biotech's development trajectory. The company revealed positive preclinical data for its lead ADC candidate, which demonstrated enhanced tumor targeting and reduced off-target toxicity in recent studies.

In a strategic move to secure long-term financial stability, NextCure extended its cash runway into 2027 through cost optimization initiatives and operational efficiencies. Management highlighted that these measures would allow the firm to advance multiple clinical programs without immediate capital raises.

The stock opened 3% higher on the news, reflecting market optimism about NextCure's ability to navigate the competitive ADC landscape while maintaining financial flexibility. Analysts noted that the company's focus on precision medicine aligns with growing industry trends toward targeted therapies.

Futures contracts for major U.S. indices suggest a lower opening for Wall Street on January 24, 2026, as investors react to global economic data and corporate earnings reports. The Dow Jones Industrial Average futures are down 0.5%, while the S&P 500 and Nasdaq Composite futures show declines of 0.7% and 1.0%, respectively. Market analysts attribute the anticipated drop to concerns over inflationary pressures and potential interest rate hikes by central banks. Traders will closely monitor key economic indicators, including the U.S. Consumer Price Index (CPI) report scheduled for release later this week, which could further influence market sentiment. Despite the negative outlook, some investors remain optimistic about long-term growth prospects in technology and renewable energy sectors.

South Korean electronics component manufacturer Samsung Electro-Mechanics Co. Ltd. (KRX: 009150) reported a rise in fourth-quarter earnings on January 23, 2026, and announced an increase in its dividend payout. The company reaffirmed its growth outlook for the upcoming fiscal year. Financial details were not disclosed, but analysts noted the positive developments as supportive of investor confidence in the firm's performance amid a competitive market landscape.

Coinbase (COIN-US) CEO Brian Armstrong's opposition to a key Senate cryptocurrency bill has triggered a rare public backlash from the White House, highlighting deep divisions within the U.S. crypto industry over legislative strategy. Following Armstrong's intervention, White House crypto advisor Patrick Witt criticized his stance that "no bill is better than a bad bill," warning that political dynamics could shift unfavorably for the sector.

The delay of the bill, now expected to be postponed by weeks, has prompted industry introspection on whether aggressive resistance during a relatively favorable political climate may have backfired.分歧 is emerging between those advocating for maximum concessions and others pushing for pragmatic compromises to secure regulatory clarity.

With midterm elections looming, concerns are mounting that a shift in congressional power could lead to stricter crypto regulations. Analysts at Bloomberg Intelligence have lowered their forecast for the bill's passage this year from 70% to 60%, cautioning further delays could diminish its chances significantly.

Armstrong later softened his position, acknowledging excessive concessions to traditional finance in the draft but maintaining belief in its potential passage. While Coinbase declined comment, Armstrong's actions underscore the crypto industry's influence in Washington under Trump, who has long supported digital assets and amassed wealth in the sector.